Advertisement

Topics

Transgene's Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration

11:46 EDT 4 Jun 2018 | FinanzNachrichten

Pexa-Vec selectively targets tumor tissue after intravenous (i. v.) administration and stimulates the adaptive and innate anti-tumor immune response Pexa-Vec induces expression of PD-L1 and PD-1 p...

Original Article: Transgene's Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration

NEXT ARTICLE

More From BioPortfolio on "Transgene's Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration"

Advertisement
Quick Search
Advertisement
Advertisement